A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics

Hoffmann-La Roche32,277 enrolled

Overview

This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.

Study Type

OBSERVATIONAL

Enrollment

32,277

Conditions

Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma * Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer Exclusion Criteria: * Participants not living in the city or representative region of the study center

Locations (31)

Unnamed facility

Adana, Turkey (Türkiye)

Outcomes

Primary Outcomes

Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region

Time frame: 36 months

Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region

Time frame: 36 months

Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region

Time frame: 36 months

Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region

Time frame: 36 months

Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region

Time frame: 36 months

Secondary Outcomes

Percentage of Participants Categorized by Tumor Size

Time frame: 36 months

Percentage of Participants Categorized by Histopathology Diagnosis

Time frame: 36 months

Percentage of Participants Categorized by the Staging System

Time frame: 36 months

Percentage of Participants Categorized by Surgery Type

Time frame: 36 months

Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.